Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia

Platelets

Volumn 26, Issue 1, 2015, Pages 83-86

  González López, Tomás José ^a   Sánchez González, Blanca ^b   Pascual, Cristina ^c   Arefi, Maryam ^d   De Cabo, Erik ^e   Alonso, Arancha ^f   Martín Salces, Mónica ^g   Jiménez Bárcenas, Reyes ^h   Calbacho, María ⁱ   Galan, Pilar ^j   Barez, Abelardo ^k   González Porras, José Ramón ^l  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e HOSPITAL EL BIERZO   (Spain)

^f Hospital Universitario Quiron Madrid   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j Hospital Mateu Orfilia de Mahón   (Spain)

^k Hospital Provincial   (Spain)

^l HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Eltrombopag; Immune thrombocytopenia; Sustained response

Indexed keywords

ELTROMBOPAG; IMMUNOGLOBULIN; RITUXIMAB; ROMIPLOSTIM; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; CHRONIC IMMUNE THROMBOCYTOPENIA; CLINICAL ARTICLE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGONISTS; BLOOD; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ADULT; AGED; BENZOATES; FEMALE; HUMANS; HYDRAZINES; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84921525787     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.870987     Document Type: Article

References (12)

1. Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009;27:424-430.
2. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.
3. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebocontrolled trial. Lancet 2009;373:641-648.
4. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
5. Newland A, Cervinek L, Eggermann J, Lefrere F, Kreuzbauer G. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim - Four European case studies. Haematologica 2011;96:98.
6. Bussel JB, Rodeghiero F, Lyons RM, Firstenberg B, Joseph J, Kessler CM, Terriou L, Stasi R, Chang P, Jun S. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: Report of 9 cases. Blood (ASH Annual Meeting Abstracts) 2011;118: Abstract 3281.
7. Vlachaki E, Papageorgiou V, Klonizakis F, Spandonidou M, Chisan S, Vetsiou E, Ioannidou E. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep 2011;3:58-59.
8. Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia (ITP): A pooled analysis of 13 clinical trials. Eur J Haematol. 2013 Aug 8 [Epub ahead of print].
9. Leven E, Miller A, Boulad N, Haider A, Bussel JB. Successful discontinuation of eltrombopag treatment in patients with chronic ITP. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 1085.
10. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol 2013; 160:538-546.
11. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013 [Epub ahead of print].
12. Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639-4645.